{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T02:31:02Z","timestamp":1768012262502,"version":"3.49.0"},"reference-count":9,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2021,1,30]]},"DOI":"10.1536\/ihj.20-442","type":"journal-article","created":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T22:09:18Z","timestamp":1610748558000},"page":"193-196","source":"Crossref","is-referenced-by-count":4,"title":["Intravenous Mineralocorticoid Receptor Antagonist Use in Acutely Decompensated Heart Failure with Diuretic Resistance"],"prefix":"10.1536","volume":"62","author":[{"given":"Nicolas","family":"Girerd","sequence":"first","affiliation":[{"name":"Universit\u00e9 de Lorraine, INSERM, Centre d'Investigations Cliniques 1433, CHRU de Nancy, Inserm 1116 and INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN Network"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthieu","family":"Aubry","sequence":"additional","affiliation":[{"name":"Department of Cardiology, European Society of Hypertension Excellence Center, H\u00f4pital de la Croix-Rousse et H\u00f4pital Lyon Sud, Hospices Civils de Lyon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Lantelme","sequence":"additional","affiliation":[{"name":"Department of Cardiology, European Society of Hypertension Excellence Center, H\u00f4pital de la Croix-Rousse et H\u00f4pital Lyon Sud, Hospices Civils de Lyon"},{"name":"Universit\u00e9 de Lyon, CREATIS, CNRS UMR5220, INSERM U1044, INSA-Lyon, Universit\u00e9 Claude Bernard Lyon 1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Huttin","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, INSERM, Centre d'Investigations Cliniques 1433, CHRU de Nancy, Inserm 1116 and INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN Network"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, INSERM, Centre d'Investigations Cliniques 1433, CHRU de Nancy, Inserm 1116 and INI-CRCT (Cardiovascular and Renal Clinical Trialists) F-CRIN Network"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Girerd N, Collier T, Pocock S, <i>et al<\/i>. Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial. Eur Heart J 2015; 36: 2310-7.","DOI":"10.1093\/eurheartj\/ehv273"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Girerd N, Pang PS, Swedberg K, <i>et al<\/i>. Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial. Eur J Heart Fail 2013; 15: 1228-35.","DOI":"10.1093\/eurjhf\/hft100"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Jobs A, Abdin A, de Waha-Thiele S, <i>et al<\/i>. Angiotensin-converting-enzyme inhibitors in hemodynamic congestion: a meta-analysis of early studies. Clin Res Cardiol 2019; 108: 1240-8.","DOI":"10.1007\/s00392-019-01456-4"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Butler J, Anstrom KJ, Felker GM, <i>et al<\/i>. Efficacy and safety of spironolactone in acute heart failure: The ATHENA-HF randomized clinical trial. JAMA Cardiol 2017; 2: 950-8.","DOI":"10.1001\/jamacardio.2017.2198"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Overdiek HW, Merkus FW. The metabolism and biopharmaceutics of spironolactone in man. Rev Drug Metab Drug Interact 1987; 5: 273-302.","DOI":"10.1515\/DMDI.1987.5.4.273"},{"key":"6","unstructured":"6. Ceremuzy\u0144ski L, Budaj A, Michorowski B. Single-dose i.v. Aldactone for congestive heart failure: a preliminary observation. Int J Clin Pharmacol Ther Toxicol 1983; 21: 417-21."},{"key":"7","unstructured":"7. Cristodorescu R, Puschita M, Deutsch G, Berger E, Luca C. The effect of intravenous potassium canrenoate in patients with severe heart failure and digitalis toxicity. Med Intern 1977; 15: 27-34."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ruggenenti P, Remuzzi G. Worsening kidney function in decompensated heart failure: treat the heart, don&apos;t mind the kidney. Eur Heart J 2011; 32: 2476-8.","DOI":"10.1093\/eurheartj\/ehr242"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Rossignol P, Girerd N, Bakris G, <i>et al<\/i>. Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. Eur J Heart Fail 2017; 19: 792-9.","DOI":"10.1002\/ejhf.688"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/62\/1\/62_20-442\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,30]],"date-time":"2021-01-30T03:54:55Z","timestamp":1611978895000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/62\/1\/62_20-442\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,30]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.20-442","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,30]]}}}